ESTHER LUC PELISSIER: Open Payments
NPI 1477978781 · ORLANDO, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,490 in 128 payments from 11 companies in 2025. Trend: 2023 $24 · 2024 $664 · 2025 $2,490
Food & beverage: $2,382Education: $108
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 29 | $702 |
| Teva Pharmaceuticals USA, Inc. | 20 | $393 |
| E.R. Squibb & Sons, L.L.C. | 24 | $319 |
| Janssen Pharmaceuticals, Inc | 13 | $231 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $214 |
| Otsuka America Pharmaceutical, Inc. | 10 | $184 |
| Vanda Pharmaceuticals Inc. | 9 | $152 |
| Luye Pharma (USA) Ltd. | 6 | $136 |
| Alkermes, Inc. | 4 | $79 |
| Noven Therapeutics, LLC | 2 | $40 |
Products named: INGREZZA, COBENFY, UZEDY, INVEGA SUSTENNA, CAPLYTA, ABILIFY ASIMTUFII, FANAPT, ERZOFRI EXTENDED-RELEASE.
Industry payments across FL — which companies pay providers there.
